Genetic translocations and the risk for more aggressive forms of prostate cancer

A research group at Memorial Sloan-Kettering Cancer Center has published data indicating that translocation and/or deletion of the  TMPRSS2-ERG fusion gene  — which occurs in about 50 percent of the cases of clinically localized prostate cancer — is not, in fact, a prognostic indicator of risk for a more aggressive type of disease. … READ MORE …